Evaluation of a Quadrivalent Influenza HA Stem Vaccine SteMos1 With and Without ALFQ Adjuvant in Healthy Adults for Flu Prevention
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-10-20
56
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new quadrivalent influenza HA stem vaccine called VRC-FLUMOS0122-00-VP SteMos1 with and without the ALFQ adjuvant in healthy adults aged 18 to 50. The study aims to assess the safety, tolerability, and immune response of this vaccine and to determine if adding the ALFQ adjuvant enhances immune responses. This phase I, open-label, dose escalation trial involves multiple groups receiving different doses and combinations of the vaccine and adjuvant.
Participants receive two doses of the SteMos1 vaccine, either alone or combined with 0.5 ml of ALFQ adjuvant, administered by injection into the upper arm muscle on Day 0 and Week 16. Groups include varying doses of 60 mcg or 180 mcg of the vaccine with or without the adjuvant, and a fifth optional group with a dose chosen based on interim safety data. The trial includes detailed safety reviews after initial participants in each group to guide enrollment progression.
During the 68-week study period, participants attend 12 clinic visits and 4 phone calls for monitoring through the influenza season. After each vaccination, participants are observed for 30 minutes and keep a 7-day diary of symptoms and temperature. Blood and mucosal samples are collected regularly to assess immune responses, and participants may opt for apheresis to collect white blood cells. Safety assessments include clinical exams and lab tests to monitor health changes and vaccine effects.
CONDITIONS
Brief Title
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Research Team
V
VRC Clinic
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
SteMos1 (HA stem nanoparticle) ± ALFQ
Standard seasonal flu vaccine
What it is
An investigational quadrivalent HA stem nanoparticle influenza vaccine (SteMos1) tested with or without the ALFQ adjuvant
A licensed seasonal influenza vaccine targeting currently circulating influenza strains
Role in trial
Investigational study intervention evaluated for safety and immunogenicity
Not part of the study; used here for external clinical reference
Primary use
Being evaluated as a new preventive influenza vaccine approach
Used each year to prevent seasonal influenza illness
How it is given or performed
Injected into muscle in a two‑dose regimen, with or without ALFQ, as defined in the dose‑escalation trial
Administered by injection following licensed vaccine protocols
Evidence status
Early human safety and immunogenicity being evaluated, but no outcomes yet
Extensive evidence supports annual use to reduce flu illness
Important risks
Risks are not yet established beyond early monitoring in the trial
Well‑characterized safety profile from routine use
Important limitations
Findings will be limited to healthy adults 18‑50 and early safety/immunogenicity; not efficacy evidence yet
Vaccine composition changes yearly and strain match varies in effectiveness
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 50Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Healthy adults aged 18 to 50 years, inclusive
Received at least one licensed influenza vaccine from the 2020-2021 through 2024-2025 seasons
In good general health based on history, physical exam, and lab tests
Able and willing to complete informed consent and read English materials
Available for clinic visits for 68 weeks including through the 2025-2026 flu season
Provide proof of identity as required
Body Mass Index (BMI) less than or equal to 35
Agree not to receive any other licensed influenza vaccine during the study
Willing to provide blood and mucosal samples for research
Laboratory tests within normal limits or approved by the study doctor
For women of childbearing potential: negative pregnancy test and agreement to use effective birth control from 21 days before enrollment through study end
You will not qualify if you...
Women who are breastfeeding or planning pregnancy during the study
Receipt of any licensed influenza vaccine or confirmed flu infection within 6 months before enrollment
Planned receipt of 2025-2026 or 2026-2027 licensed influenza vaccines
Live vaccines within 4 weeks or inactivated vaccines within 2 weeks prior to enrollment
mRNA vaccines within 4 weeks prior to enrollment
Receipt of specific investigational influenza vaccines
Use of systemic immunosuppressive or cytotoxic medications within 4 weeks prior or any within 14 days before enrollment
Blood products received within 16 weeks prior
Use of investigational agents within 4 weeks prior or planned during the study
Current allergy immunotherapy unless on maintenance
Current tuberculosis treatment or prevention
History of serious vaccine reactions preventing study vaccination
Certain immune, blood, neurological, or chronic diseases as specified
Any condition judged by the study doctor to impair consent or participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Vaccination
Duration - 16 weeks
Participants receive two vaccine injections in the upper arm muscle on Day 0 and Week 16, either SteMos1 alone or combined with the ALFQ adjuvant. They are monitored for 30 minutes after each shot and complete a 7-day symptom diary.
2 visits (in-person)
Follow-up and Monitoring
Duration - Up to 68 weeks
Participants attend clinic visits and phone calls over about 68 weeks for safety monitoring, blood and mucosal sample collection, and health assessments. Some may opt for additional blood cell collection by apheresis.
10 clinic visits and 4 phone calls
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
5
Similar Trials
Phase I Study Evaluating Dose, Safety, and Immune Response of Mosaic Hexavalent Influenza Vaccine FluMos-v2 With or Without ALFQ Adjuvant in Healthy Adults
Evaluation of a Quadrivalent Influenza HA Stem Vaccine SteMos1 With and Without ALFQ Adjuvant in Healthy Adults for Flu Prevention